Investor Presentation - First Six Months of 2021
131
Investor presentation First six months of 2021
Novo NordiskⓇ
US insulin net prices have declined in recent years, but
vulnerable patients rely on our affordability offerings
The US population by health
insurance coverage
Private insurance schemes
| Government insurance schemes
48%
8%
Uninsured
Net price development for
NovoLogⓇvial
Net price¹
Index
200
180
160
44%
140
.
120
115
100
80
60
40
20
333 million people
0
2001 2004 2007 2010 2013 2016 2019
Novo Nordisk insulin affordability
offerings in the US
Follow-on brand fast-acting (NovologⓇ) and
premix insulin (Novolog® Mix) with 50% list price
discount vs branded versions
My$99Insulin 30-day supply of a combination of
Novo Nordisk insulin products (up to 3 vials or 2
packs of pens) for USD 99
• Patient Assistance Program free diabetes
medication to people in need, annual income
<400% above government defined poverty.
Program expanded during COVID-19 outbreak
⚫ Human insulin for about USD25/vial at national
pharmacies, including Walmart and CVS
Immediate supply a short-term, immediate-need
program offering free insulin for those at risk of
rationing
Note: Government insurance schemes cover Medicare, Medicaid and public exchanges, some of these with high deductibles Source: Census.gov; Congressional Budget
Office Health Insurance Coverage 2016-2026; Medicare Enrolment Dashboard; CMS Health Insurance Enrolment Projection 2015-2025; Medicaid and CHIP Enrolment Report
Oct 2017; CMS Insurance Marketplace Fact sheet 2017; CDC.gov¹ Adjusted for inflation
•
Co-pay Savings Cards providing USD -250 million
in assistance in 2019
•
In 2020, more than 1 million people reachedView entire presentation